Skip to content

Study on the changing pattern of blood proteomics and metabolomics after MWA for elderly early lung cancer

CT-guided microwave ablation for the treatment of early-stage lung cancer in the elderly to improve the safety and efficacy evaluation of key technology research-Study on the changing pattern of blood proteomics and metabolomics after MWA for elderly early lung cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400082548
Enrollment
Unknown
Registered
2024-04-01
Start date
2024-04-01
Completion date
Unknown
Last updated
2024-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Case series:None

Sponsors

Beijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 100 Years

Inclusion criteria

Inclusion criteria: (1) Signed informed consent, age =65 years old; (2) Pathologically confirmed diagnosis of lung cancer, determined to be early stage by PET-CT, enhanced CT and other imaging examinations (AJCC 9th edition stage ?A, ?B, ?A, i.e., tumor diameter =5cm, no lymph nodes and distant metastases); (3) Eastern Cooperative Oncology Group Performance Status (ECOG PS) score 0-3; (4) Inability to tolerate or refusal of surgery and radiotherapy; (5) Primary patients who, in addition to supportive therapy, did not receive any other adjuvant therapy before residual, recurrent, or metastatic tumor was detected; (6) The treatment process cooperates with the provision of clinicopathological data and imaging data required for the research process, cooperates with the follow-up and collection of blood from the evaluation nodes, and agrees to use the test data for the follow-up research.

Exclusion criteria

Exclusion criteria: (1) Severe bleeding and coagulation disorders, platelets less than 50 x 109/L; (2) Eastern Oncology Collaborative Physical Status Score >3; (3) Severe systemic infection, high fever (>38.5°C), skin infection and breakdown at the puncture site; (4) Combination of other malignant tumors; (5) Those with incomplete information or unable to comply with the study protocol.

Design outcomes

Primary

MeasureTime frame
Patterns of change in proteomic and metabolomic patterns in preoperative and postoperative MWA;Association of related molecular pathways with post-ablation syndrome;

Countries

China

Contacts

Public ContactXiao-guang Li

Beijing Hospital

xglee88@126.com+86 156 9975 7271

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026